Abstract
Aim:
To explore the potential of electroporation (EP)-mediated hepatitis B virus (HBV) DNA vaccination for the treatment of chronic HBV infection.
Methods:
BALB/c mice were vaccinated with HBV DNA vaccine encoding for the HBV preS2-S antigen, combined with or without EP. HBV surface antigen expression plasmid was administered into mice liver via a hydrodynamic injection to mimic HBV infection. The clearance of antigen in the serum and liver was detected by ELISA assay and immunohistochemical staining. The histopathology of the liver tissues was examined by HE staining and serum alanine aminotransferase assay.
Results:
The immunogenicity of HBV DNA vaccine encoding for the HBV preS2-S antigen can be improved by EP-mediated vaccine delivery. The elicited immune responses can indeed reduce the expression of HBV surface antigen (HBsAg) in hepatocytes of the mouse model that was transfected to express HBsAg using the hydrodynamic injection method. The antigen clearance process did not cause significant toxicity to liver tissue, suggesting a non-cytolytic mechanism.
Conclusion:
The EP-aided DNA vaccination may have potential in mediating viral clearance in chronic hepatitis B patients.
Similar content being viewed by others
Article PDF
References
World Health Organization Expert Committee on Biological Standardization. Requirements for hepatitis B vaccine. Bull World Health Organ 1988; 66: 443–55.
Buendia MA . Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 1992; 59: 167–226.
Maupas P, Goudeau A, Coursaget P, Drucker J, Bagros P . Immunization against Hepatitis B in man. Lancet 1976; 1: 1367–70.
Vitiello A, Ishioka G, Grey HM, Rose R, Farness P, LaFond R, et al. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. J Clin Invest 1995; 95: 341–9.
Thimme R, Chang KM, Pemberton J, Sette A, Chisari FV . Degenerate immunogenicity of an HLA-A2-restricted hepatitis B virus nucleocapsid cytotoxic T lymphocyte epitope that is also presented by HLA-B51. Virology 2001; 75: 3984–7.
Wen YM, Wu XH . Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995; 345: 1575–6.
Davis HL . DNA vaccines for prophylactic or therapeutic immunization against hepatitis B virus. Mt Sinai J Med 1999; 66: 84–90.
Thermet A, Rollier C, Zoulim F, Trepo C, Cova L . Progress in DNA vaccine for prophylaxis and therapy of hepatitis B. Vaccine 2003; 21: 659–62.
Sallberg M, Hughes L, Javadian A, Ronlov G, Hultgren C, Townsend K, et al. Genetic immunization of chimpanzees chronically infected with the hepatitis B virus, using a recombinant retroviral vector encoding the hepatitis B virus core antigen. Hum Gen Ther 1998; 9: 1719–29.
Gregoriadis G, Saffie R, de Souza JB . Liposome-mediated DNA vaccination. FEBS Lett 1997; 402: 107–10.
Fuller JT, Fuller DH, McCabe D, Haynes JR, Widera G . Immune responses to hepatitis B virus surface and core antigens in mice, monkeys, and pigs after Accell particle-mediated DNA immunization. Ann NY Acad Sci 1995; 772: 282–4.
Selby M, Goldbeck C, Pertile T, Walsh R, Ulmer J . Enhancement of DNA vaccine potency by electroporation in vivo. J Biotechnol 2000; 83: 147–52.
Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M, et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635–40.
Zhao YG, Peng BW, Deng HW, Chen GM, Yang FQ, Shao M, et al. Anti-HBV immune responses in rhesus macaques elicited by electroporation mediated DNA vaccination. Vaccine 2006; 24: 897–903.
Oka Y, Akbar SM, Horiike N, Joko K, Onji M . Mechanism and therapeutic potential of DNA-based immunization against the envelope proteins of hepatitis B virus in normal and transgenic mice. Immunology 2001; 103: 90–7.
Liu F, Song YK, Liu D . Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258–66.
Zhang G, Budker V, Wolff JA . High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gen Ther 1999; 10: 1735–7.
Tong SP, Li JS, Vitvitski L, Trepo C . Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology 1990; 176: 596–603.
He XQ, Chen GM, Huang Y . Construction and identification of therapeutic double plasmid HBV DNA vaccine. Med J Chin PLA 2003; 28: 493–6.
Harty JT, Tvinnereim AR, White DW . CD8 + T cell effector mechanisms in resistance to infection. Annu Rev Immunol 2000; 18: 275–308.
Kaech SM, Wherry EJ, Ahmed R . Effector and memory T cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 4: 251–62.
Doolan DL, Hoffman SL . The complexity of protective immunity against liver-stage malaria. J Immunol 2000; 165: 1453–62.
Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV . Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996; 4: 25–36.
Pancholi P, Lee DH, Liu QY, Tackney C, Taylor P, Perkus M, et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001; 33: 448–54.
Ketzinel-Gilad M, Zauberman A, Nussbaum O, Shoshany Y, Ben-Moshe O, Pappo O, et al. The use of the hydrodynamic HBV animal model to study HBV biology and anti-viral therapy. Hepatol Res 2006; 34: 228–37.
Guidotti LG, Ando K, Hobbs MV, Ishikawa T, Runkel L, Schreiber RD, et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc Natl Acad Sci USA 1994; 91: 3764–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Project supported by grants from the National Natural Science Foundation of China (No 30571721) and the Fok Ying Tong Education Foundation (No 91035).
Rights and permissions
About this article
Cite this article
Peng, Jl., Zhao, Yg., Mai, Jh. et al. Non-cytolytic antigen clearance in DNA-vaccinated mice with electroporation. Acta Pharmacol Sin 28, 1024–1030 (2007). https://doi.org/10.1111/j.1745-7254.2007.00591.x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1111/j.1745-7254.2007.00591.x
Keywords
This article is cited by
-
Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver
Cancer Gene Therapy (2012)